Cargando…

Arthralgia resolution rate following chikungunya virus infection

BACKGROUND: Arthralgia, persistent pain or stiffness of the joints, is the hallmark symptom of chronic chikungunya virus (CHIKV) disease. Associated with significant disability and reduced quality of life, arthralgia can persist for many months following CHIKV infection. Understanding the expected d...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Driscoll, Megan, Salje, Henrik, Chang, Aileen Y., Watson, Hugh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627389/
https://www.ncbi.nlm.nih.gov/pubmed/34492392
http://dx.doi.org/10.1016/j.ijid.2021.08.066
_version_ 1784606844781592576
author O'Driscoll, Megan
Salje, Henrik
Chang, Aileen Y.
Watson, Hugh
author_facet O'Driscoll, Megan
Salje, Henrik
Chang, Aileen Y.
Watson, Hugh
author_sort O'Driscoll, Megan
collection PubMed
description BACKGROUND: Arthralgia, persistent pain or stiffness of the joints, is the hallmark symptom of chronic chikungunya virus (CHIKV) disease. Associated with significant disability and reduced quality of life, arthralgia can persist for many months following CHIKV infection. Understanding the expected duration of arthralgia persistence is important for managing clinical expectations at the individual-level as well as for estimating long-term burdens on population health following a CHIKV epidemic. METHODS: A review of cohort studies reporting the prevalence of arthralgia post-CHIKV infection over multiple time points was conducted. Generalized linear models were used to estimate the average rate of arthralgia resolution following CHIKV infection. RESULTS: Sixteen cohort studies matching the inclusion criteria were identified and included in the analysis. An average rate of arthralgia resolution of 10.85% (95% confidence interval (CI) 9.05–12.66%) per month was estimated across studies, corresponding to an expected median time to arthralgia resolution of 6.39 months (95% CI 5.48–7.66 months) and an expected arthralgia prevalence of 72.21% (95% CI 68.40–76.23%) at 3 months post-CHIKV infection. CONCLUSIONS: Estimates of the average rate of arthralgia resolution and the expected prevalence of arthralgia over time post-CHIKV infection were derived. These can help inform expectations regarding the long-term public health burdens associated with CHIKV epidemics.
format Online
Article
Text
id pubmed-8627389
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86273892021-12-03 Arthralgia resolution rate following chikungunya virus infection O'Driscoll, Megan Salje, Henrik Chang, Aileen Y. Watson, Hugh Int J Infect Dis Article BACKGROUND: Arthralgia, persistent pain or stiffness of the joints, is the hallmark symptom of chronic chikungunya virus (CHIKV) disease. Associated with significant disability and reduced quality of life, arthralgia can persist for many months following CHIKV infection. Understanding the expected duration of arthralgia persistence is important for managing clinical expectations at the individual-level as well as for estimating long-term burdens on population health following a CHIKV epidemic. METHODS: A review of cohort studies reporting the prevalence of arthralgia post-CHIKV infection over multiple time points was conducted. Generalized linear models were used to estimate the average rate of arthralgia resolution following CHIKV infection. RESULTS: Sixteen cohort studies matching the inclusion criteria were identified and included in the analysis. An average rate of arthralgia resolution of 10.85% (95% confidence interval (CI) 9.05–12.66%) per month was estimated across studies, corresponding to an expected median time to arthralgia resolution of 6.39 months (95% CI 5.48–7.66 months) and an expected arthralgia prevalence of 72.21% (95% CI 68.40–76.23%) at 3 months post-CHIKV infection. CONCLUSIONS: Estimates of the average rate of arthralgia resolution and the expected prevalence of arthralgia over time post-CHIKV infection were derived. These can help inform expectations regarding the long-term public health burdens associated with CHIKV epidemics. Elsevier 2021-11 /pmc/articles/PMC8627389/ /pubmed/34492392 http://dx.doi.org/10.1016/j.ijid.2021.08.066 Text en © 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
O'Driscoll, Megan
Salje, Henrik
Chang, Aileen Y.
Watson, Hugh
Arthralgia resolution rate following chikungunya virus infection
title Arthralgia resolution rate following chikungunya virus infection
title_full Arthralgia resolution rate following chikungunya virus infection
title_fullStr Arthralgia resolution rate following chikungunya virus infection
title_full_unstemmed Arthralgia resolution rate following chikungunya virus infection
title_short Arthralgia resolution rate following chikungunya virus infection
title_sort arthralgia resolution rate following chikungunya virus infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627389/
https://www.ncbi.nlm.nih.gov/pubmed/34492392
http://dx.doi.org/10.1016/j.ijid.2021.08.066
work_keys_str_mv AT odriscollmegan arthralgiaresolutionratefollowingchikungunyavirusinfection
AT saljehenrik arthralgiaresolutionratefollowingchikungunyavirusinfection
AT changaileeny arthralgiaresolutionratefollowingchikungunyavirusinfection
AT watsonhugh arthralgiaresolutionratefollowingchikungunyavirusinfection